Minimal Residual Disease Detection in Mantle Cell Lymphoma: Technical Aspects and Clinical Relevance
- 1 July 2011
- journal article
- research article
- Published by Elsevier in Seminars in Hematology
- Vol. 48 (3), 172-184
- https://doi.org/10.1053/j.seminhematol.2011.05.002
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotypingLeukemia, 2010
- Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyBlood, 2010
- Quantitative monitoring of cyclin D1 expression: A molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphomaInternational Journal of Cancer, 2008
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupBlood, 2008
- Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinationsHaematologica, 2008
- Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease EradicationClinical Cancer Research, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR dataLeukemia, 2007
- Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell LymphomaTransplantation and Cellular Therapy, 2006
- Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkBlood, 2005